Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 2190-2193, 2004; 10.1373/clinchem.2004.034371
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borderie, D.
Right arrow Articles by Kahan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borderie, D.
Right arrow Articles by Kahan, A.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2004;50:2190-2193.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

High Ischemia-Modified Albumin Concentration Reflects Oxidative Stress But Not Myocardial Involvement in Systemic Sclerosis

Didier Borderie1,1,a, Yannick Allanore2,1, Christophe Meune3, Jean Y. Devaux3, Ohvanesse G. Ekindjian1 and André Kahan2

Departments of1 Biochemistry A,2 Rheumatology A, and3 Nuclear Medicine, Paris V University, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France;

aaddress correspondence to this author at: Service de Biochimie A, 27 rue du faubourg Saint-Jacques, 75014 Paris, France; fax 33-1-5841-1585, e-mail didier.borderie@cch.ap-hop-paris.fr

The first 300 words of the full text of this article appear below.

Systemic sclerosis (SSc) is a connective tissue disease characterized by widespread vascular lesions and fibrosis of the skin and internal organs. In SSc, vasospasm causes frequent episodes of reperfusion injury and free-radical-mediated endothelial disruption. Primary myocardial involvement is far more common than initially suspected on clinical grounds (1)(2)(3)(4)(5) and affects survival rates because it is associated with a poor prognosis (6)(7). Myocardial fibrosis is thought to occur secondarily to repeated focal ischemia in the coronary microcirculation as a result of abnormal vasoreactivity, with or without associated structural vascular disease (4)(5). The early and accurate identification of cardiac involvement is therefore of paramount clinical importance.

The concentration of ischemia-modified albumin (IMA), as measured by the albumin cobalt binding test (Ischemia Technologies, Inc.), is a new marker to rule out transient myocardial ischemia (8)(9). This test measures the binding of exogenous cobalt to the NH2 terminus of human albumin. In the presence of myocardial ischemia, structural changes occur in the NH2 terminus of albumin, rapidly reducing its capacity to bind transition metal ions after an ischemic event (10).

We assessed the accuracy of the albumin cobalt binding test for detecting ischemia in SSc patients and investigated the roles of myocardial ischemia and peripheral oxidative stress in this condition. We also considered carbonyl residues and advanced oxidation protein products (AOPP) as factors indicative of protein oxidation.

We included consecutive patients hospitalized for systematic follow-up who fulfilled the American Rheumatism Association preliminary criteria for SSc. The exclusion criteria were pregnancy; symptoms of heart failure, including class III or IV dyspnea (New York Heart Association); venous distension and recent major lower limb edema; pulmonary arterial hypertension (systolic arterial pressure >40 mmHg . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Pathol.Home page
P O Collinson and D C Gaze
Ischaemia-modified albumin: clinical utility and pitfalls in measurement
J. Clin. Pathol., September 1, 2008; 61(9): 1025 - 1028.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
E. Giannitsis and H. A. Katus
Ability of DNase I activity to detect myocardial ischaemia in vasospastic angina a view through a monocle?
Eur. Heart J., December 2, 2007; 28(24): 2955 - 2956.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
E. Giannitsis and H. A. Katus
Mirror, mirror on the wall: the quest for the earliest marker of myocardial ischaemia
Eur. Heart J., November 2, 2005; 26(22): 2349 - 2350.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. M. van der Zee, H. J. Verberne, J. P. van Straalen, G. T.B. Sanders, B. L.F. Van Eck-Smit, R. J. de Winter, and J. C. Fischer
Ischemia-Modified Albumin Measurements in Symptom-Limited Exercise Myocardial Perfusion Scintigraphy Reflect Serum Albumin Concentrations but Not Myocardial Ischemia
Clin. Chem., September 1, 2005; 51(9): 1744 - 1746.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.